Press Releases

Press Releases

    Date Title View
    06/24/22
    Summary ToggleNew Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)
    PDF Version
    06/15/22
    Summary ToggleHorizon Therapeutics plc Submits Regulatory Filing for UPLIZNA® (inebilizumab) in Brazil
    PDF Version
    06/15/22
    Summary ToggleHorizon Therapeutics plc Named One of the Fortune Best Workplaces in Chicago™
    PDF Version
    06/11/22
    Summary ToggleAnalysis of Pooled Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials Reinforces Safety Profile in People with Thyroid Eye Disease (TED)
    PDF Version
    06/09/22
    Summary ToggleHorizon Therapeutics plc Named a Top Company for Executive Women
    PDF Version
    06/06/22
    Summary ToggleHorizon Therapeutics plc to Present at the Goldman Sachs 43rd Annual Global Health Care Conference
    PDF Version
    06/02/22
    Summary ToggleHorizon Therapeutics plc to Highlight Data and Education on Thyroid Eye Disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference
    PDF Version
    06/01/22
    Summary ToggleData Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (pegloticase injection) Plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reactions) Compared to KRYSTEXXA Monotherapy
    PDF Version
    05/31/22
    Summary ToggleHorizon Therapeutics plc Wins 2022 International CSR Excellence Award for #RAREis Adoption Fund
    PDF Version
    05/31/22
    Summary ToggleAnalysis from the Phase 3 N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA® (inebilizumab-cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations
    PDF Version
    Displaying 1 - 10 of 665 results